54.95 USD
-0.46 (-0.83%)
54.95 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 84% to CRNX. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 85.75. This target is 56.06% above the current price.
- CRNX was analyzed by 22 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about CRNX.
- In the previous month the buy percentage consensus was at a similar level.
- CRNX was analyzed by 22 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2026-01-12 | Goldman Sachs | Upgrade | Neutral -> Buy |
| 2026-01-08 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2026-01-06 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-11-07 | Citizens | Maintains | Market Outperform -> Market Outperform |
| 2025-09-30 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-09-29 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2025-09-29 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-09-26 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-09-26 | Baird | Maintains | Outperform -> Outperform |
| 2025-09-26 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-09-24 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-08-11 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-06-27 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-25 | Stifel | Initiate | Buy |
| 2025-02-28 | Citizens Capital Markets | Maintains | Market Outperform -> Market Outperform |
| 2025-02-04 | Wolfe Research | Initiate | Peer Perform |
| 2025-01-22 | Jefferies | Upgrade | Hold -> Buy |
| 2025-01-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-16 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-11-14 | Citigroup | Maintains | Buy -> Buy |
| 2024-11-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-09-27 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-09-16 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-08-09 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-08-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-07-09 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-07-02 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-06-28 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-04 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-06-04 | Oppenheimer | Maintains | Outperform -> Outperform |
CRINETICS PHARMACEUTICALS IN / CRNX FAQ
What is the average price target for CRINETICS PHARMACEUTICALS IN (CRNX) stock?
22 analysts have analysed CRNX and the average price target is 85.75 USD. This implies a price increase of 56.06% is expected in the next year compared to the current price of 54.95.
How do analysts rate CRINETICS PHARMACEUTICALS IN (CRNX)?
The consensus rating for CRINETICS PHARMACEUTICALS IN (CRNX) is 83.6364 / 100 . This indicates that analysts generally have a positive outlook on the stock.